Ansa Biotechnologies
Next-generation DNA synthesis using enzymes
Y CombinatorWinter 2020ActiveHealthcareIndustrial BioSynthetic BiologyBiotech
What they do
Problem
Traditional chemical DNA synthesis is slow, error-prone, and limited in scalability, constraining biotech and biological research progress.
Solution
Ansa Biotechnologies uses enzyme-based next-generation DNA synthesis to produce DNA faster, cleaner, and more accurately than chemical methods.
Who it's for
Biotech and pharma companies, diagnostics developers, and academic or industrial research labs that need custom DNA synthesis.
Founders
Dan Lin-Arlow
Founder
Sebastian Palluk
Founder
Company timeline
- Founded2018
- YC batchWinter 2020
- StatusActive
- Team size72 people
- LocationEmeryville, CA, USA
Similar startups
Quince Therapeutics
Quince TherapeuticsQuince Therapeutics (fka Cortexyme) is a late-stag…
Entelexo Biotherapeutics
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
BioAge Labs
Antibiotics work by killing bacteria, stopping infections from runnin…
Helix Nanotechnologies
Next-generation mRNA platform to solve cancer, COVID and climate.
Elegen
Fast, reliable, and accurate DNA synthesis (including at long lengths…